MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia"

  • 2018 International Congress

    Early gastrointestinal dysfunction is predictive of faster progression in Parkinson’s disease

    M. Camacho, J. Evans,, D. Breen, G. Cummins, R. Wijeyekoon, K. Scott, T. Stoker, R. Barker, C. Williams-Gray (Cambridge, United Kingdom)

    Objective: To evaluate whether constipation at time of diagnosis has prognostic significance in terms of motor and cognitive progression in PD. Background: There is evidence…
  • 2018 International Congress

    The relationship between family care giver number and progression speed of dementia

    Y. Liu, S.L. Yang, Y.C. Wu (Shanghai, China)

    Objective: Study the fact delays dementia progression. Background: Alzheimer’s disease is unrestored yet now. Relieving the life upset of patient and postponing the disease progression…
  • 2018 International Congress

    Serum insulin-like growth factor-1 levels in parkinsonism or dementia disorders

    K. Suzuki, S. Suzuki, Y. Ishii, T. Matsubara, H. Fujita, Y. Watanabe, M. Okamura, T. Kadowaki, H. Sakuramoto, K. Hirata (Tochigi, Japan)

    Objective: To investigate serum insulin growth factor-1 (IGF-1) levels in neurodegenerative disease and to correlate clinical parameters. Background: IGF-1 is highly expressed in the central…
  • 2018 International Congress

    Nonlinearities in outcome-specific hazard of motor and nonmotor long-term complications of Parkinson’s disease

    P. Prange, T. Danaila, C. Laurencin, C. Caire, E. Metereau, H. Merle, E. Broussolle, D. Maucort-Boulch, S. Thobois (Bron, France)

    Objective: To estimate the specific hazard of motor and nonmotor milestones of Parkinson's disease (PD) progression in the long term. Background: Parkinson’s disease greatly varies…
  • 2018 International Congress

    Angiotensin-converting enzyme inhibitors are neuroprotective regarding APOE-mediated motor and non-motor experiences for Alzheimer’s dementia but not for dementia with Lewy bodies

    F. Oliveira, M. Miraldo, E. Castro-Neto, F. Machado, S. Almeida, S. Matas, P. Bertolucci, M. Naffah-Mazzacoratti (São Paulo, Brazil)

    Objective: To assess whether angiotensin-converting enzyme (ACE) inhibitors modulate associations of biofluid concentrations and activity of ACE with motor and non-motor experiences in dementia with…
  • 2018 International Congress

    A bayesian network approach for prediction of future dementia in Parkinson’s disease

    P. Surathi, M. Mirian, K. Sundvick, S. Appel-Cresswell, M. McKeown (Vancouver, BC, Canada)

    Objective: To predict subsequent development of Parkinson’s dementia using parameters which can be easily obtained in a regular clinic visit using a machine learning approach.…
  • 2018 International Congress

    No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors

    F. Hopfner, S. Müller, D. Steppat, J. Miller, N. Schmidt, K.P. Wandinger, F. Leypoldt, D. Berg, A. Franke, W. Lieb, L. Tittmann, M. Balzer-Geldsetzer, S. Baudrexel, R. Dodel, R. Hilker-Roggendorf, E. Kalbe, J. Kassubek, T. Klockgether, I. Liepelt-Scarfone, B. Mollenhauer, P. Neuser, K. Reetz, O. Riedel, C. Schulte, J. Schulz, A. Spottke, A. Storch, C. Trenkwalder, G. Deuschl, G. Kuhlenbäumer (Kiel, Germany)

    Objective: We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment (n = 297) and controls (n…
  • 2018 International Congress

    An open labeled, observational study for the Satisfaction and Preference of the Rivastigmine patch for treatment of Alzheimer’s disease and Parkinson’s disease dementia (SAFE-ADPD) in Koreans

    M. Park, D. Shin (Daegu, Republic of Korea)

    Objective: This study performed to access caregiver’s satisfaction and preference of the Rivastigmine patch for treatment of Alzheimer’s disease and Parkinson’s disease dementia patients to…
  • 2018 International Congress

    Using Vision to Predict Dementia in Parkinson’s Disease

    L-A. Leyland, R. Mahmood, S. Hewitt, M. Durteste, F. Bremner, M. Lai, L. Miller, A. Saygin, C. Song, P. Keane, A. Schrag, R. Weil (London, United Kingdom)

    Objective: To identify visual measures that relate to higher risk of dementia in Parkinson’s Disease (PD). Background: Dementia affects 50% of people with PD within…
  • 2018 International Congress

    Polysomnographic data in Dementia with Lewy Bodies: Correlation with clinical features and comparison with other alfa-synucleinopathies

    P. Bugalho, M. Salavisa, J. Marto, C. Borbinha, L. Alves (Lisbon, Portugal)

    Objective: 1) Polysomnography (PSG) assessment of sleep in Dementia with Lewy Bodies (DLB). 2) Correlation between PSG data, fluctuations and hypersomnolence. 3) Comparison of PSG…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 36
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley